- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00491413
Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth
High Dose Erythropoietin for Neonates With Asphyxia
Study Overview
Detailed Description
Damage to the central nervous system as a result of oxygen deprivation at birth is a major cause of life-long mental and developmental handicaps. When there is not enough oxygen in the blood (hypoxemia) the brain is deprived of oxygen. Some brain cells respond by producing Epo. Epo then binds to oxygen-deprived brain cells. This binding triggers chemical reactions within the brain cell that prevent cell death. Epo also reduces inflammation around the brain cells and acts as an antioxidant. In animal studies, recombinant Epo (rEpo) administration, even up to six hours after oxygen deprivation, reduced subsequent brain injury by 50% to 70%.
Epo has been used by neonatologists to stimulate erythropoiesis (red blood cell production) and reduce the incidence of blood transfusions. Doses of rEpo required for protection of brain cells are considerably higher than those traditionally used by neonatologists.
This study will evaluate the pharmacokinetics, biologic effect, and safety of high dose Epo in neonates with brain injury due to hypoxemia.
Within six hours of birth, each eligible infant will receive one dose of rEpo intravenously. Any infants who require a lumbar puncture during the first week of life will have levels of natural Epo and rEpo in their spinal fluid measured. Blood tests will be used to measure the antioxidant effect of Epo and the impact on red blood cell production. Neurodevelopmental outcome will be measured at 6 and 12 months of age.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
St. Petersburg, Florida, United States, 33701
- All Children's Hospital
-
Contact:
- Robert D. Christensen, MD
- Phone Number: 727-502-8168
- Email: rchriste@hsc.usf.edu
-
Contact:
- Stacey M. Levitt, MD
- Phone Number: 727-553-1570
- Email: slevitt@hsc.usf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Infant 6 hours of age or less
- Apgar scores less than or equal to 3 at 1 and 5 minutes
- Weight greater than 2500 grams (5.5 lbs)
- Central venous line in place
Exclusion Criteria
- infants are ineligible if they do not meet the inclusion criteria above
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Investigators
- Principal Investigator: Robert D. Christensen, MD, University of South Florida
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21HD042308 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asphyxia
-
Sharp HealthCareSharp Mary Birch Hospital for Women & NewbornsActive, not recruitingBirth Asphyxia With Neurologic InvolvementUnited States, Canada
-
Massachusetts General HospitalUnited States Agency for International Development (USAID); Grand Challenges...Active, not recruitingPerinatal Asphyxia | Asphyxia Neonatorum | Birth AsphyxiaUnited States
-
Massachusetts General HospitalCompletedPerinatal Asphyxia | Asphyxia Neonatorum | Birth Asphyxia
-
University of Health Sciences LahoreNot yet recruiting
-
Sharp HealthCareSharp Mary Birch Hospital for Women & NewbornsCompleted
-
Universidad Peruana Cayetano HerediaGrand Challenges Canada; Instituto Nacional de Salud del Niño. Lima, PeruCompleted
-
Sheri Kashmir Institute of Medical SciencesCompletedPerinatal Asphyxia , Moderate to Severe HIEIndia
-
Pia WintermarkWalimu; Kawempe National Referral Hospital; Saint Francis Memorial HospitalRecruiting
-
Sheri Kashmir Institute of Medical SciencesCompleted
-
Tanta UniversityCompleted
Clinical Trials on epoetin
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
M.D. Anderson Cancer CenterCompleted
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
Hoffmann-La RocheTerminated
-
General Hospital Sveti DuhCompletedEnd Stage Renal Disease | Renal Anemia | Regular Dialysis TreatmentCroatia
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumors | Lymphomas | Chemotherapy-induced Symptomatic Anemia | Malignant Hemopathies | MyelomasFrance
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedKidney Diseases | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous